CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. (CALC) reported that director Frederic Guerard received a grant of 10,000 Director Stock Options on 2026-08-19. Each option allows purchase of one share of common stock at an exercise price of $0.6131 per share and expires on 2036-08-18. According to the vesting terms, 1/12th of the options vest in equal monthly installments over one year following the grant date, and the options will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Guerard holds 10,000 derivative securities directly.
CalciMedica, Inc. (CALC) reported that director Evgeny Zaytsev, through Bering Partners II, L.P., was granted two series of warrants, each covering 1,450,267 shares of common stock, with exercise prices of $0.8033 and $1.00 per share, respectively. Both warrants become exercisable on or after August 19, 2026 and are subject to a 9.99% beneficial ownership cap. In addition, Zaytsev received a directly held director stock option for 10,000 shares at an exercise price of $0.6131 per share, vesting in monthly installments over one year and expiring on August 18, 2036.
CalciMedica, Inc. (CALC) reported that director Robert N. Wilson received derivative awards on August 19, 2026. He was granted two warrants for 1,182,621 shares each of common stock, with exercise prices of $0.8033 and $1.00 per share, acquired under a Securities Purchase Agreement approved by an independent board committee. These warrants are exercisable starting August 19, 2026, subject to a 19.99% beneficial ownership limitation and specified expiration dates tied to December 25, 2027 or 30 days after public disclosure of FDA clearance of CM5480, and June 25, 2031, respectively. Wilson also received a stock option for 10,000 shares at an exercise price of $0.6131 per share, vesting in 12 equal monthly installments over one year and in any event fully vesting by the 2027 annual meeting of stockholders.
CalciMedica, Inc. (CALC) reported that Chief Medical Officer Sudarshan Hebbar received two warrant awards linked to a Securities Purchase Agreement dated June 23, 2026, with a June 25, 2026 closing, approved by an independent board committee. Each warrant covers 124,486 shares of Common Stock, one with a $0.8033 per-share exercise price expiring as early as December 25, 2027 and the other with a $1.00 exercise price expiring on June 25, 2031. Both become exercisable on or after August 19, 2026 and are subject to a beneficial ownership cap not exceeding 19.99%.
CalciMedica, Inc. (CALC) reported that its Chief Business Officer and director, Eric W. Roberts, acquired two warrant awards to purchase common stock. Each warrant covers 186,729 shares of common stock, one with an exercise price of $0.8033 per share expiring on December 25, 2027, and another with an exercise price of $1.00 per share expiring on June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and were issued under a Securities Purchase Agreement dated June 23, 2026, approved by an independent board committee. Each warrant includes a 19.99% ownership cap, limiting exercises that would cause the holder and its affiliates to exceed that percentage of CalciMedica’s outstanding common stock, subject to adjustment with 61 days’ notice.
CalciMedica, Inc. (CALC) reported that its Chief Executive Officer, A. Rachel Leheny, received two warrant grants on August 19, 2026, each for 186,729 warrants to purchase common stock. One warrant has an exercise price of $0.8033 and expires December 25, 2027, with an earlier end date possible 30 days after public disclosure of clearance of the Investigational New Drug Application for CM5480 by the U.S. Food and Drug Administration. The other has an exercise price of $1.00 and expires June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and are subject to a beneficial ownership limitation not to exceed 19.99%. The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, approved by an independent committee of the board.
CalciMedica, Inc. (CALC) is the subject of an amended Schedule 13D in which Bering Partners II, L.P., its general partner Bering Partners II GP, L.L.C., and individuals Evgeny Zaytsev and Philip M. Sawyer report beneficial ownership of 3,553,398 shares of common stock in aggregate, representing 9.99% of the class. This stake consists of 2,113,513 common shares plus warrants exercisable within 60 days for an additional 1,439,885 shares, including Common Stock Warrants and Series A and Series B Warrants.
The filing states that stockholder approval for issuing the Series A and Series B Warrants was obtained on August 19, 2026, and these warrants held by Bering II were issued the same day. A 9.99% Beneficial Ownership Limitation in the Series A and B Warrants prevents exercise that would push ownership above this threshold, so further warrant shares (an additional 795,650 from each of Series A and B) are excluded from the reported beneficial ownership. The reporting persons state they have shared voting and dispositive power over the reported shares and have not engaged in other transactions in CalciMedica securities in the past 60 days.
CalciMedica, Inc. (CALC) reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares of common stock authorized for issuance under the plan by 7,500,000 and revising how the annual automatic share reserve increase is calculated.
Stockholders elected two Class III directors to terms through the 2029 annual meeting, ratified Baker Tilly US, LLP as independent auditor for 2026, and approved, on an advisory basis, executive compensation and an annual say‑on‑pay frequency. They also approved an amendment to the certificate of incorporation to permit a reverse stock split in a range of 1‑for‑2 to 1‑for‑10, with a proportional reduction in authorized common shares, to be implemented at the Board’s discretion.
In addition, stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of Series A and Series B common stock warrants and related shares under a June 23, 2026 Securities Purchase Agreement, and, under Rule 5635(c), similar warrant issuances to certain directors and officers.
Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, reported beneficial ownership of 2,489,729 shares of CalciMedica, Inc. common stock. This represents 8.1% of the company’s outstanding common stock.
Woodline Partners reported sole voting and sole dispositive power30,736,401 shares
Armistice Capital, LLC and Steven Boyd report a significant holding in CalciMedica, Inc. They disclose beneficial ownership of 3,411,361 shares of CalciMedica common stock, representing 9.99% of the class. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported.
The shares are directly held by Armistice Capital Master Fund Ltd., while Armistice Capital serves as investment manager under an Investment Management Agreement and may be deemed to beneficially own the securities. Steven Boyd, as managing member of Armistice Capital, may also be deemed a beneficial owner. The Master Fund has the right to receive dividends and sale proceeds from the reported securities.